Skip to main content

West Pharmaceutical Services, I (WST) Stock Analysis

Range Bound setup

HoldModerate Confidence

Healthcare · Medical Instruments & Supplies

Hold if already holding. Not a fresh buy at $303.93, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: international (outside U.S.) (56.7%); Analyst target reached - limited upside remaining.

West Pharmaceutical Services manufactures containment and delivery systems for injectable drugs—rubber stoppers, seals, drug delivery devices, and contract-manufactured components—for biologic, generic, and pharmaceutical companies globally. Top 10 customers represent 47.6% of... Read more

$303.93+0.1% A.UpsideScore 6.0/10#3 of 25 Medical Instruments & Supplies
QualityF-score9 / 9FCF yield1.28%
IncomeYield0.29%(5y avg 0.25%)Payout11.50%sustainable
Stop $284.75Target $304.37(analyst − 13%)A.R:R 0.0:1
Analyst target$349.85+15.1%13 analysts
$304.37our TP
$303.93price
$349.85mean
$400

Hold if already holding. Not a fresh buy at $303.93, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: international (outside U.S.) (56.7%); Analyst target reached - limited upside remaining. Chart setup: RSI 57 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Score 6.0/10, moderate confidence.

Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 64d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.

Val3.6Qual7.2Grw8.8Mom3.3Sent6.8Ins5.0Peer5.9Tech6.1Risk6.36.0OVERALL

Recent Developments — West Pharmaceutical Services, I

Latest news

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
V7 quality resilience bonus: +0.2 (Q=7.2 in RISK_OFF)
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (4/4)
Risks
Concentration risk — Geographic: international (outside U.S.) (56.7%)
Analyst target reached - limited upside remaining
Expensive valuation

Key Metrics

P/E (TTM)40.6
P/E (Fwd)31.8
Mkt Cap$21.5B
EV/EBITDA24.5
Profit Mgn16.8%
ROE19.1%
Rev Growth21.0%
Beta1.17
Dividend0.29%
Rating analysts23

Quality Signals

Piotroski F9/9MoatWideCompounder✓

Options Flow

P/C1.35bearish
IV40%normal
Max Pain$250-17.7% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHGeographicinternational (outside U.S.)57%
    10-K Item 1: 'Sales outside of the U.S. accounted for 56.7% of our consolidated net sales in 2025'
  • MEDIUMCustomertop 10 customers48%
    10-K Item 1: 'Our ten largest customers accounted for 47.6% of our consolidated net sales in 2025'
  • LOWCustomerone customer (>10% of net sales)16%
    10-K Item 1: 'one of these customers individually accounted for more than 10% of consolidated net sales, at 15.8%'

Material Events(8-K, last 90d)

  • 2026-03-09Item 5.02HIGH
    CEO Eric M. Green informed the Board on March 6, 2026 of his intent to retire once his successor is hired to ensure a smooth transition. Board engaging executive search firm; transition expected in second half of 2026. No successor named.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers·1 ceiling hit

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd
0.0
Volume
0.5
Obv
4.5
Rsi
5.5
Ma Position
6.0
Above 200-day MA

Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static

Ev Ebitda
0.0
Pe
3.0
Forward Pe
3.6
Peg Ratio
3.6
Analyst Target
5.0
Ps
5.7
Forward P/E: 31.8xPEG: 3.14
GatesMomentum 3.3<4.5A.R:R 0.0 < 1.5@spotInsider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 64d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRange BoundSuitability: Moderate
RSI
57 · Neutral
↓ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $271.93Resistance $330.88

Price Targets

$285
$304
A.Upside+0.1%
A.R:R0.0:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! Target reached (0.1% upside)
! Momentum score 3.3/10 — below 4.5 minimum
! Reward/Risk 0.0:1 at current price — below 1.5:1 minimum

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-07-23 (64d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is WST stock a buy right now?

Hold if already holding. Not a fresh buy at $303.93, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: international (outside U.S.) (56.7%); Analyst target reached - limited upside remaining. Chart setup: RSI 57 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Target $304.37 (+0.1%), stop $284.75 (−6.7%), A.R:R 0.0:1. Score 6.0/10, moderate confidence.

What is the WST stock price target?

Take-profit target: $304.37 (+0.1% upside). Target $304.37 (+0.1%), stop $284.75 (−6.7%), A.R:R 0.0:1. Stop-loss: $284.75.

What are the risks of investing in WST?

Concentration risk — Geographic: international (outside U.S.) (56.7%); Analyst target reached - limited upside remaining; Expensive valuation.

Is WST overvalued or undervalued?

West Pharmaceutical Services, I trades at a P/E of 40.6 (forward 31.8). TrendMatrix value score: 3.6/10. Verdict: Hold.

What do analysts say about WST?

23 analysts cover WST with a consensus score of 4.1/5. Average price target: $350.

What does West Pharmaceutical Services, I do?West Pharmaceutical Services manufactures containment and delivery systems for injectable drugs—rubber stoppers, seals,...

West Pharmaceutical Services manufactures containment and delivery systems for injectable drugs—rubber stoppers, seals, drug delivery devices, and contract-manufactured components—for biologic, generic, and pharmaceutical companies globally. Top 10 customers represent 47.6% of net sales; international sales account for 56.7% of consolidated net sales in 2025. The company operates in two segments: Proprietary Products and Contract-Manufactured Products.

Related stocks: NVST (Envista Holdings Corporation) · RMD (ResMed Inc.) · MMSI (Merit Medical Systems, Inc.) · TFX (Teleflex Incorporated) · ISRG (Intuitive Surgical, Inc.)